General Information of Drug (ID: DMTIM1E)

Drug Name
PMID26161698-Compound-34 Drug Info
Cross-matching ID
TTD Drug ID
DMTIM1E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Samuraciclib DM54FQA Breast cancer 2C60-2C65 Phase 1/2 [3]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [5]
SY-1365 DMK48PM Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
LY3405105 DMB51K2 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
SY-5609 DMNW3LH Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [1]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [1]
Tricyclic benzimidazole derivative 1 DM5SD9E N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 7 (CDK7) TTQYF7G CDK7_HUMAN Inhibitor [1]

References

1 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
3 The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
4 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
5 Clinical pipeline report, company report or official report of BioTheryX.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
8 Clinical pipeline report, company report or official report of Syros Pharmaceuticals.